Isatuximab plus bortezomib, lenalidomide, and dexamethasone for transplant-ineligible newly diagnosed multiple myeloma patients: a frailty subgroup analysis of the IMROZ trial by Salomon Manier, Meletios-Athanasios Dimopoulos, Xavier P. Leleu, Philippe Moreau, Michele Cavo, Hartmut Goldschmidt, Robert Z. Orlowski, Muriel Tron, Christina Tekle, Marie-France Brégeault, Andrea T. Shafer, Meral Beksac, Thierry Facon

Get full text